{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:26Z","timestamp":1793383166505,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n A long-acting monoclonal antibody (nirsevimab) for use in infants aged 7 months or younger and an antenatal respiratory syncytial virus (RSV) vaccine (RSVpreF) became available in Washington state in 2023.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the combined population-level impact of nirsevimab and antenatal RSV vaccine on the relative rate of RSV-associated hospitalizations and emergency department (ED) visits among infants during the first 2 respiratory seasons of use.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This difference-in-diferrences cohort study used data from the Washington state syndromic surveillance program on RSV-associated hospitalizations and ED visits among infants from July 1, 2022, to June 30, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Introduction of nirsevimab for infants and antenatal RSVpreF.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A difference-in-differences analysis was conducted to estimate mean relative changes in the rate of RSV-associated hospitalizations and ED visits between the period before and the period after introduction of RSV prevention products for children aged 7 months or younger (treatment group) beyond that for children aged 8 to 24 months (comparison group) using negative binomial models. Relative changes were estimated separately for July 1, 2023, to June 30, 2024, and July 1, 2024, to June 30, 2025, vs July 1, 2022, to June 30, 2023.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n During July 2022 to June 2025, there were 16\u202f775 RSV-associated hospitalizations and ED visits among children aged 24 months or younger in Washington state (median age, 10 months [IQR, 4-19 months]; 9228 male [55%]). The median age increased from 9 months (IQR, 3-19 months) during 2022-2023 to 12 months (IQR, 6-21 months) during 2024-2025. During the first year of limited use of RSV prevention products (2023-2024), estimates did not indicate a significant decrease in the rate of RSV-associated hospitalizations and ED visits among children aged 7 months or younger beyond temporal trends also observed for children aged 8 to 24 months (ratio of relative rates, 0.92 [95% CI, 0.80-1.03]). In the second year of use (2024-2025), there was an estimated 43.0% (95% CI, 32.0%-52.1%) relative decrease in the rate of RSV-associated hospitalizations and ED visits among children aged 7 months or younger beyond that for children aged 8 to 24 months. Relative changes were similar across racial groups, except for Native Hawaiian or Other Pacific Islander children. The estimated impact in 2024-2025 was 1.77 times (95% CI, 1.17-2.66 times) higher for White vs Native Hawaiian or Other Pacific Islander children.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of children aged 24 months or younger, nirsevimab and antenatal RSVpreF vaccine were associated with a reduced burden of RSV-associated hospitalization and ED visits among infants aged 7 months or younger. Results support continued use of these products in the state. Increased coverage will likely be associated with additional decreases in severe disease burden, particularly among populations at increased risk.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.5695","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:00:24Z","timestamp":1775660424000},"page":"e265695","source":"Crossref","is-referenced-by-count":4,"title":["RSV Prevention Products and Severe RSV-Associated Disease Among Infants"],"prefix":"10.1001","volume":"9","author":[{"given":"Julia C.","family":"Bennett","sequence":"first","affiliation":[{"name":"Washington State Department of Health, Shoreline"},{"name":"Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Bevers","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Chronister","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"McHugh","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Choudry","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Huynh","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"},{"name":"Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Englund","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lindquist","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Holshue","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Shoreline"},{"name":"Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"10098","key":"zoi260203r1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"zoi260203r2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","article-title":"Respiratory syncytial virus infection: an illness for all ages.","volume":"38","author":"Walsh","year":"2017","journal-title":"Clin Chest Med"},{"issue":"6","key":"zoi260203r3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"41","key":"zoi260203r4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus\u2013associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"zoi260203r5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi260203r6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first respiratory syncytial virus season\u2014New Vaccine Surveillance Network, October 2023-February 2024.","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi260203r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.33535","article-title":"Nirsevimab administration and RSV hospitalization in the 2024-2025 season.","volume":"8","author":"Pelletier","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260203r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101196","article-title":"Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.","volume":"49","author":"Payne","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"16","key":"zoi260203r10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.15585\/mmwr.mm7416a1","article-title":"Interim evaluation of respiratory syncytial virus hospitalization rates among infants and young children after introduction of respiratory syncytial virus prevention products\u2014United States, October 2024-February 2025.","volume":"74","author":"Patton","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"zoi260203r13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"zoi260203r14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/cid\/ciae140","article-title":"Increased pediatric respiratory syncytial virus case counts following the emergence of SARS-CoV-2 can be attributed to changes in testing.","volume":"78","author":"Petros","year":"2024","journal-title":"Clin Infect Dis"},{"key":"zoi260203r15","doi-asserted-by":"publisher","author":"Chow","journal-title":"Nat Rev Microbiol","DOI":"10.1038\/s41579-022-00807-9"},{"issue":"14","key":"zoi260203r16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of respiratory syncytial virus\u2014United States, 2017-2023.","volume":"72","author":"Hamid","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi260203r17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060435","article-title":"RSV among American Indian and Alaska Native children: 2019 to 2020.","volume":"152","author":"Atwell","year":"2023","journal-title":"Pediatrics"},{"issue":"31","key":"zoi260203r19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"Respiratory syncytial virus immunization coverage among infants through receipt of nirsevimab monoclonal antibody or maternal vaccination\u2014United States, October 2023-March 2024.","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"zoi260203r21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of clesrovimab for prevention of severe respiratory syncytial virus\u2013associated lower respiratory tract infections in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2025.","volume":"74","author":"Moulia","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"zoi260203r23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41587-025-02713-w","article-title":"Merck\u2019s anti-RSV antibody expands protection for infants.","volume":"43","author":"Marshall","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"3","key":"zoi260203r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0522","article-title":"Race and ethnicity data in electronic health records\u2014striving for clarity.","volume":"7","author":"Yemane","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260203r7","unstructured":"Bartelt? K, Gasser? J, Higgs? E, Gracianette? M, Barkley? E. Maternal RSV vaccine effective in reducing RSV infections and hospitalizations in infants. Published online January 21, 2025. Accessed December 18, 2025. https:\/\/epicresearch.org\/articles\/maternal-rsv-vaccine-effective-in-reducing-rsv-infections-and-hospitalizations-in-infants"},{"key":"zoi260203r11","unstructured":"Syndromic surveillance (RHINO). Washington State Department of Health. Accessed June 26, 2025. https:\/\/doh.wa.gov\/public-health-provider-resources\/healthcare-professions-and-facilities\/data-exchange\/syndromic-surveillance-rhino"},{"key":"zoi260203r12","unstructured":"Population estimates. Washington State Office of Financial Management. Accessed June 26, 2025. https:\/\/ofm.wa.gov\/washington-data-research\/population-demographics\/population-estimates"},{"key":"zoi260203r18","unstructured":"Limited availability of nirsevimab in the United States\u2014interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023\u20132024 respiratory virus season. October 23, 2023. Accessed July 23, 2025. https:\/\/www.cdc.gov\/han\/2023\/han00499.html"},{"key":"zoi260203r20","unstructured":"U.S. FDA approves Merck\u2019s ENFLONSIATM (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. Merck.com. June 9, 2025. Accessed July 24, 2025. https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir\/"},{"key":"zoi260203r22","unstructured":"Jenco? M. CDC director OKs new RSV immunization for infants. American Academy of Pediatrics. Accessed August 16, 2025. https:\/\/publications.aap.org\/aapnews\/news\/32796\/CDC-director-OKs-new-RSV-immunization-for-infants?"},{"key":"zoi260203r24","unstructured":"ENFLONSIATM (clesrovimab-cfor) injection, for intramuscular use. Food and Drug Administration. Published online June 2025. Accessed August 16, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761432s000lbl.pdf"},{"key":"zoi260203r25","unstructured":"BEYFORTUS (nirsevimab-alip) injection, for intramuscular use. Food and Drug Administration. Accessed August 16, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847512\/bennett_2026_oi_260203_1788549708.5233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:00:20Z","timestamp":1789138820000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.5695","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]}}}